Skip to main content
Article thumbnail
Location of Repository

In silico regulatory analysis for exploring human disease progression

By Dustin T Holloway, Mark Kon and Charles DeLisi
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2464594
Provided by: PubMed Central

Suggested articles

Citations

  1. (1996). 3rd: Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene
  2. (1997). A clinical overview of WT1 gene mutations. Human Mutation
  3. (1996). A non-AUG translational initiation event generates novel WT1 isoforms.
  4. (2001). A novel method of protein secondary structure prediction with high segment overlap measure:support vector machine approach.
  5. (2004). A o z a s a K , M o n d e n M , S u g i y a m a H : Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Anticancer Research
  6. (2006). A: FGFR3 mutations in benign skin tumors. Cell Cycle
  7. (2002). A: Inhibition of PDE3B Augments PDE4 Inhibitor-induced Apoptosis in a Subset of Patients with Chronic Lymphocytic Leukemia. Clin Cancer Res
  8. (1991). A: Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours. Anticancer Res
  9. (1999). A: WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene.
  10. (1999). AG: Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties.
  11. (2004). AJ: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell
  12. (1993). AJ: WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science
  13. (1998). Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlates with clinicopathological parameters. Genes, Chromosomes and Cancer
  14. (1991). Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA
  15. (1998). Analysis of WT1 target gene expression in stably transfected cell lines. Oncogene
  16. (1995). Antagonism of WT1 activity by protein self-association.
  17. (1999). AS: WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene.
  18. (2003). Aspects of tuberous sclerosis complex (TSC) protein function in the brain. Biochem Soc Trans
  19. (2005). Assessing computational tools for the discovery of transcription factor binding sites. Nature Biotechnology
  20. (2005). AT: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer
  21. (1995). Atweh G: The tumor suppressor gene WT1 inhibits ras-mediated transformation. Oncogene
  22. (1990). Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science
  23. (2005). Bonavida B: Expression of transcription factor Yin Yang 1 in prostate cancer.
  24. (1993). BR: Expression of the Wilms' tumor suppressor gene WT1 during mouse embryogenesis. Cell Growth Differ
  25. (1993). BR: Homozygous somatic Wt1 point mutations in sporadic unilateral Wilms tumor.
  26. (2000). BR: Identification of connective tissue growth factor as a target of WT1 transcriptional regulation.
  27. (1996). BR: Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation.
  28. (2006). Breast tumor copy number aberration phenotypes and genomic instability.
  29. (2004). Brivanlou AH: Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor.
  30. (2004). Brivanlou AH: Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nature Medicine
  31. (2005). Chromatin immunoprecipitation (ChIP) on chip experiments uncover a widespread distribution of NF-Y binding CCAAT sites outside of core promoters.
  32. (2008). Classifying transcription factor targets and discovering relevant biological features. Biology Direct
  33. (1994). Clericuzio CL: "Molecular genetic analysis of the WT1 gene in patients suspected to have the Denys-Drash syndrome". Med Pediatric Oncology
  34. (2004). Combining pattern discovery and discriminant analysis to predict gene coregulation. Bioinformatics
  35. (1996). Coordinate Positioning of MEF2 and Myogenin Binding Sites. Gene
  36. Crispino JD: Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
  37. (2006). CS: A Critical Role for Tetraspanin
  38. (1998). DA: E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells. Oncogene
  39. (1997). DA: Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res
  40. (1999). DA: The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell
  41. (1995). DA: The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev
  42. (1995). DA: WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis.
  43. (2003). Database for Annotation, Visualization, and Integrated Discovery. Genome Biol
  44. (2006). DC: How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res
  45. (1990). DE: An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell
  46. (1991). DE: WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature
  47. (1993). Denys-Drash syndrome: relating a clinical disorder to genetic alterations in the tumor suppressor gene WT1. J Pediatr
  48. (1995). Deuel TF: Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways. Oncogene
  49. (2002). DF: CBFA2T3 (MTG16) Is a Putative Breast Tumor Suppressor Gene from the Breast Cancer Loss of Heterozygosity Region at 16q24.3. Cancer Res
  50. (1993). Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nat Genet
  51. (2000). DNA Binding Sites: Representation and Discovery. Bioinformatics
  52. (1999). DR: Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1. Exp Cell Res
  53. (1994). E: Beckwith-Wiedemann syndrome.
  54. (2003). E: Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours. Biochem Soc Trans
  55. (2003). Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells.
  56. (1997). Efstratiadis A: Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes. Genes Dev
  57. (1999). Egeler RM: Genetics of Wilms' tumor. Seminars in Urologic Oncology
  58. (1986). Ehrenfeucht A: Information content of binding sites on nucleotide sequences.
  59. (2007). Eizirik D: In silico identification of NFkappaB-regulated genes in pancreatic beta-cells.
  60. (1993). Ekstrom TJ: IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat Genet
  61. (1994). EN: Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. Development
  62. (2006). Ensembl 2006. Nucleic Acids Res
  63. (2006). EPD in its twentieth year: towards complete promoter coverage of selected model organisms. Nucleic Acids Res
  64. (2003). Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. Oncol Rep
  65. (2006). Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations.
  66. (1998). Extracting Regulatory Sites from the Upstream Region of Yeast Genes by Computational Analysis of Oligonucleotide Frequencies.
  67. Fast kernels for inexact string matching.
  68. (1996). Feinberg AP: Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA
  69. (1994). Fine structure analysis of the WT1 gene in sporadic Wilms tumors.
  70. (1993). FJ 3rd: Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus.
  71. (2005). Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis
  72. (1990). GA: Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature
  73. (2002). Gene Selection for Cancer Classification using Support Vector Machines. Machine Learning
  74. (2005). Genome-wide promoter extraction and analysis in human, mouse, and rat. Genome Biology
  75. (1992). Germline intronic and exonic mutations in the Wilms' tumour gene (WT1) affecting urogenital development. Nat Genet
  76. (2004). Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14. Human Mutation
  77. (1996). GF: Differential Function of Wilms' Tumor Gene WT1 Splice Isoforms in Transcriptional Regulation.
  78. (1999). GF: Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1. Anticancer Res
  79. (1997). GF: The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Mullerian-inhibiting substance, and the androgen receptor. Clin Cancer Res
  80. (2004). Gingeras TR: Unbiased Mapping of Transcription Factor Binding Sites along Human Chromosomes 21 and 22 Points to Widespread Regulation of Noncoding RNAs. Cell
  81. (2004). Haussler D: Combining Phylogenetic and Hidden Markov Models in Biosequence Analysis.
  82. (2005). Haussler D: Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res
  83. (2000). Haussler D: Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics
  84. (2002). Henske EP: Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene
  85. (2006). High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. Clin Cancer Res
  86. (2004). Hoffman EP: Embryonic myogenesis pathways in muscle regeneration. Dev Dyn
  87. (2001). Hua : Support vector machine approach for protein subcellular localization prediction. Bioinformatics
  88. (2005). Huff V: Genome-wide loss of heterozygosity analysis of WT1-wildtype and WT1-mutant Wilms tumors. Genes Chromosomes Cancer
  89. (2002). Identification and expression analysis of the human mu-protocadherin gene in fetal and adult kidneys.
  90. (2003). Increased Activation of CCAAT/Enhancer Binding Protein-{beta} Correlates with the Invasiveness of Renal Cell Carcinoma. Clin Cancer Res
  91. (1998). Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70. Genes Dev
  92. (2004). Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncology Reports
  93. (2005). Integrating genomic data to predict transcription factor binding. Genome Informatics
  94. (2006). Introduction to Data Mining.
  95. (2005). Ioannou P: Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death.
  96. (1990). Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell
  97. (1994). JA: Towards a genetic basis for kidney development. Mechanisms of Development
  98. (1993). JB: The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mechanisms of Development
  99. (2005). K-C: Using string kernel to predict signal peptide cleavage site based on subsite coupling model. Amino Acids
  100. (2000). K-R: Engineering support vector machine kernels that recognize translation initiation sites. Bioinformatics
  101. (2006). Kel AE, Wingender E: TRANSFAC(R) and its module TRANSCompel(R): transcriptional gene regulation in eukaryotes. Nucleic Acids Res
  102. (1994). Kim SJ: Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol
  103. (1999). Krolewski AS: Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus.
  104. (1994). KW: Autoregulation of the human WT1 gene promoter.
  105. (2004). L: OCT4: A sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res
  106. (2001). L: The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D receptor.
  107. (1995). LeRoith D: Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol
  108. (2000). Licht JD: Ecadherin is a WT1 target gene.
  109. (1995). Licht JD: WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins.
  110. Lin C-J: LIBSVM: a Library for Support Vector Machines.
  111. (1997). LM: The WT1 protein is a negative regulator of the normal bcl-2 allele in t(14;18) lymphomas.
  112. (1994). Loss of heterozygosity for chromosomes 16q and p1 in Wilms' tumors predicts an adverse outcome. Cancer Research
  113. (2006). Machine Learning for Predicting Targets of Transcription Factors
  114. (2007). Machine Learning for Regulatory Analysis and Transcription Factor Target Prediction in Yeast. Systems and Synthetic Biology
  115. (2006). Machine Learning Methods for Transcription Data Integration.
  116. (2001). Malik KT: The molecular biology of Wilms' tumor. Expert Reviews in Molecular Medicine
  117. (2005). Mapping DNA-protein interactions in large genomes by sequence tag analysis of genomic enrichment. Nature Methods
  118. (2006). Mechanisms controlling embryonic stem cell self-renewal and differentiation. Crit Rev Eukaryot Gene Expr
  119. (1999). MM: The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter. Cell Growth Differ
  120. (1999). Morisaki T: Expression of MEF2 genes during human cardiac development. Tohoku J Exp Med
  121. (2004). MS: Antagonism between DNA hypermethylation and enhancer-blocking activity at the H19 DMD is uncovered by CpG mutations. Nat Genet
  122. (2004). MS: Role of H19 3' sequences in controlling H19 and Igf2 imprinting and expression. Genomics
  123. (1994). Nasu K: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood
  124. (1992). ND: Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci USA
  125. (2003). Oosterhuis JW: POU5F1 (OCT3/4) Identifies Cells with Pluripotent Potential in Human Germ Cell Tumors. Cancer Res
  126. (2006). Orkin SH: A protein interaction network for pluripotency of embryonic stem cells. Nature
  127. (1998). orphan nuclear receptor SF-1 in sex-specific gene expression. Cell
  128. (2003). Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Science
  129. (2004). Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Science
  130. (2004). Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer Science
  131. Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer.
  132. (2006). Patsouris E: FGFR-2 and -3 play an important role in initial stages of oral oncogenesis. Anticancer Res
  133. (1988). Pearson P: Molecular nature of genetic changes resulting in loss of heterozygosity of chromosome 11 in Wilms' tumours. Human Genetics
  134. (1996). Perbal B: Regulation of nov by WT1: a potential role for nov in nephrogenesis. Oncogene
  135. (2001). Pesole G: An algorithm for finding signals of unknown length in DNA sequences. Bioinformatics
  136. (2006). Pesole G: MoD Tools: regulatory motif discovery in nucleotide sequences from co-regulated or homologous genes. Nucleic Acids Res
  137. (2004). Pesole G: Weeder Web: discovery of transcription factor binding sites in a set of sequences from co-regulated genes. Nucleic Acids Res
  138. (2000). Physical and functional interaction between the HCMV IE2 protein and the Wilms' tumor suppressor WT1. Biochem Biophys Res Commun
  139. (2001). Polonsky KS: Molecular Mechanisms and Clinical Pathophysiology of Maturity-Onset Diabetes of the Young.
  140. (1993). Polychronakos C: Parental genomic imprinting of the human IGF2 gene. Nat Genet
  141. (1999). Probabilistic Outputs for Support Vector Machines and Comparisons to Regularized Likelihood Methods.
  142. (2004). RA: Control of Pancreas and Liver Gene Expression by HNF Transcription Factors. Science
  143. (2005). RA: Core transcriptional regulatory circuitry in human embryonic stem cells. Cell
  144. (2005). Radvanyi F: Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet
  145. (2005). Rajpert-De Meyts E: Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology
  146. (1995). Rauscher FJ 3rd, Ercolani L: LLC-PK1 cell growth is repressed by WT1 inhibition of G-protein alpha i2 protooncogene transcription.
  147. (2008). Rauscher FJ 3rd: Repression of the insulin-like growth factor IIBiology Direct
  148. (1992). Rauscher FJ 3rd: The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene.
  149. (1991). Rauscher FJ III: Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science
  150. (2006). Real FX: Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.
  151. (2008). Reeve AE: Constitutional relaxation of insulin-like growth fac-Biology Direct
  152. (2003). Regulatory sequence analysis tools.
  153. (1995). Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1. Oncogene
  154. (2004). RH: Defining the CREB Regulon: A Genome-Wide Analysis of Transcription Factor Regulatory Regions. Cell
  155. (1997). RJ: Organization and Myogenic Restricted Expression of the Murine Serum Response Factor Gene. A Role for Autoregulation.
  156. (1993). Roberts CT Jr: Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA
  157. (1990). Role for the Wilms Tumor Gene in Genital Development. Proc Natl Acad Sci USA
  158. (2002). Romashchenko AG: Transcription Regulatory Regions Database (TRDD): its status in 2002. Nucleic Acids Res
  159. (1995). Roosen CB: An introduction to multivariate adaptive regression splines. Stat Methods Med Res
  160. (1993). S e n s D , G a r v i n A : WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science
  161. (2006). S: Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proc Natl Acad Sci USA
  162. (2006). Saglio G: WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes. Methods in Molecular Medicine
  163. (2006). Saqi MA: Predicting deleterious nsSNPs: an analysis of sequence and structural attributes.
  164. (1994). Saunders G: Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter.
  165. (1995). Saunders GF: Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res
  166. (1995). Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol Cell Biol
  167. (1990). Sequence logos: a new way to display consensus sequences. Nucleic Acids Res
  168. (2007). Serum response factor binding sites differ in three human cell types. Genome Res
  169. Sinz F: SPIDER, object oriented machine learning library.
  170. (2006). SJM: ORegAnno: an open access database and curation system for literaturederived promoters, transcription factor binding sites and regulatory variation. Bioinformatics
  171. (2004). Smith A: Self-renewal of teratocarcinoma and embryonic stem cells. Oncogene
  172. (2006). Soejima H: Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
  173. (2003). Soejima H: Significant Reduction of WT1 Gene Expression, Possibly Due to Epigenetic Alteration in Wilms' Tumor.
  174. (1998). Statistical Learning Theory.
  175. Stormo GD: ANN-Spec: a method for discovering transcription factor binding sites with improved specificity.
  176. (1972). Strong LC: Mutation and cancer: a model for Wilms' tumor of the kidney.
  177. (1991). Structural rearrangements of the WT1 gene in Wilms' tumour cells. Oncogene
  178. (2002). Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers.
  179. (2003). Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Science
  180. (2003). Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Science
  181. (1992). Sukhatme VP: Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci USA
  182. (1994). Sukhatme VP: The Wilms' tumor suppressor gene WT1 is negatively autoregulated.
  183. (1994). Sukumar S: RNA editing in the Wilms' tumor susceptibility gene, WT1. Genes Dev
  184. (2001). Sukumar S: Wilms' Tumor Suppressor Gene (WT1) Is Expressed in Primary Breast Tumors Despite Tumor-specific Promoter Methylation. Cancer Res
  185. (2004). Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
  186. (2003). Swinnen JV: RNA Interference-mediated Silencing of the Fatty Acid Synthase Gene Attenuates Growth and Induces Morphological Changes and Apoptosis of LNCaP Prostate Cancer Cells. Cancer Res
  187. (2006). T: Differential effects of GATA-1 on proliferation and differentiation of erythroid lineage cells. Blood
  188. (1996). T: Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet
  189. (1997). T: Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of
  190. (1996). T: Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1). Oncogene
  191. (1993). TF: The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains.
  192. (1994). The Denys-Drash syndrome.
  193. (2006). The Mathworks.
  194. (2004). The molecular basis of pluripotency in mouse embryonic stem cells. Cloning And Stem Cells
  195. (1999). The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation. Mol Cell Biol
  196. (2007). Thomson JA: Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res
  197. (1991). Tilghman SM: Parental imprinting of the mouse H19 gene. Nature
  198. (1995). Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. Proc Natl Acad Sci USA
  199. (2003). TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis. Biochem Soc Trans
  200. (1999). Tumor-associated WT1 missense mutants indicate that transcriptional activation by WT1 is critical for growth control.
  201. (2003). Tycko B: Biallelic expression of HRAS and MUCDHL in human and mouse. Hum Genet
  202. (2005). Tycko B: Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res
  203. (1999). Using the Fisher kernel method to detect remote protein homologies.
  204. (2004). VisANT: an online visualization and analysis tool for biological interaction data.
  205. (2005). VisANT: data-integrating visual framework for biological networks and modules. Nucleic Acids Res
  206. (2005). Wang WL: Overexpression of Bax induces apoptosis and enhances drug sensitivity of hepatocellular cancer-9204 cells.
  207. (2006). Weng Z: A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome. Cell
  208. (2001). Wilms tumor and the WT1 gene. Exp Cell Res
  209. (2001). Wilms Tumor and the WT1 Gene. Experimental Cell Research
  210. (2003). WJ: The UCSC Genome Browser Database. Nucl Acids Res
  211. (2004). WJ: The UCSC Table Browser data retrieval tool. Nucleic Acids Res
  212. (2005). WS: Kernels for Gene Regulatory Regions.
  213. (2004). WS: Mismatch string kernels for discriminative protein classification. Bioinformatics
  214. (2002). WS: The Spectrum Kernel: A string kernel for SVM protein classification. Pac Symp Biocomput
  215. (1996). Yeung RS: Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc Natl Acad Sci USA
  216. (2006). Zhang MQ: Adaptively inferring human transcriptional subnetworks. Molecular Systems Biology
  217. (2004). Zhao B: Anti-tumor effect of hematopoietic cells carrying the gene of ribonuclease inhibitor. Cancer Gene Ther
  218. (2005). Zwarthoff EC: A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine. Clin Cancer Res
  219. (2001). ZY: Rb-associated protein 46 (RbAp46) suppresses the tumorigenicity of adenovirus-transformed human embryonic kidney 293 cells.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.